Evido Health offers LiverPRO and its pre-screening service to bridge input flexibility, direct-to-site deployment, and customised set-up for each study to accelerate MASH clinical trial recruitment.

We are on a mission to ensure timely detection of a hidden and potentially fatal chronic liver disease that one in four have without knowing it. We give people a chance to change course before it is too late. Something that is not given today. At Evido, we are fighting the global liver pandemic that Fatty Liver Disease represents. It is referred to as the new diabetes and kills more than one million people every year. Today, we lack accurate ways of detecting at-risk people in time, which leads to three out of four, not being diagnosed before it is too late. Evido is founded and anchored in years of extensive clinical research and high quality health data. We are introducing new data driven solutions to timely detect at-risk people and close a crucial gap in the field of Fatty Liver Disease.